GALVESTON, Texas, Aug. 21, 2019 /PRNewswire/ -- Chrysalis BioTherapeutics, Inc. today announced that the US Food and Drug Administration (FDA) Office of Orphan Product Development and the European Medicines Agency (EMA) have granted…
GALVESTON, Texas, Feb. 7, 2017 /PRNewswire/ -- Chrysalis BioTherapeutics, Inc. today announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases (NIH-NIAID) to develop TP508 as a countermeasure…
GALVESTON, TX, May 2, 2016. Chrysalis BioTherapeutics, Inc. today announced receipt of a $3 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National…
An interdisciplinary research team led by The University of Texas Medical Branch at Galveston reports a new breakthrough in countering the deadly effects of radiation exposure. A single injection of…
GALVESTON, Texas, Aug. 18, 2015 /PRNewswire/ -- Chrysalis BioTherapeutics, Inc. today announced publication of data demonstrating that TP508, the company's lead drug candidate, activates stem cells in the gastrointestinal (GI) system to…
We answer all email and requests as they come in. If you have an urgent matter or would like to place an order please click the link below to give us a call.
Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.